Previous 10 | Next 10 |
A look at the top 10 most actives in the United States SoFi Technologies Inc. (SOFI) fell 9.7% to $7.1068 on volume of 45,729,887 shares Tesla Inc. (TSLA) rose 11.6% to $187.7701 on volume of 45,057,076 shares Collective Audience Inc. (CAUD) rose 71.6% to $0.669199 on volume of 34,955,653...
2024-04-29 08:29:50 ET More on Soleno Therapeutics Soleno Therapeutics GAAP EPS of -$0.33 misses by $0.07 Seeking Alpha’s Quant Rating on Soleno Therapeutics Historical earnings data for Soleno Therapeutics Financial information for Soleno Therapeutics...
First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024 REDWOOD CITY, Calif., April 29, 2024 (GLOBE NEW...
2024-03-07 10:01:04 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
2024-03-06 16:47:28 ET More on Soleno Therapeutics Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families Seeking Alpha’s Quant Rating on Soleno Therapeutics Historical earnings data for Soleno Therapeutics Financial information...
REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth...
Soleno Therapeutics, Inc. (NASDAQ: SLNO) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.83% on the day to $48.66. Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for t...
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Offic...
2024-01-22 22:42:14 ET Summary ACADIA Pharmaceuticals and Soleno Therapeutics are both conducting late-stage trials for the treatment of Prader-Willi Syndrome. PWS is a rare disease characterized by various physical and developmental challenges. Acadia is an established commer...
2024-01-22 11:54:46 ET More on highly-shorted stocks Spirit Airlines: Don't Join The Panic Spirit Airlines: Ch.11 Bankruptcy Could Be A Better Option To Save The Airline Assessing JetBlue Airways During A Time Of Significant Uncertainty Over Spirit Airlines Turmoil ...
News, Short Squeeze, Breakout and More Instantly...
Soleno Therapeutics Inc. Company Name:
SLNO Stock Symbol:
NASDAQ Market:
REDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), ("Soleno" or the "Company"), a clinical-stage bi...
REDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today launched a groundbreaking in...
2024-05-14 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...